Last reviewed · How we verify
NCT03761836
Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique
NA trial testing ShangRing in Circumcision, Male. Withdrawn.
30 September 2021
Quick facts
| Lead sponsor | Jhpiego |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 November 2020 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 3 locations across Mozambique |
Drugs / interventions tested
- ShangRing
Conditions studied
- Circumcision, Male — all drugs for Circumcision, Male →
Sponsor
Jhpiego — full company profile →
Who can join
13 and older, male only, with Circumcision, Male. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm interventional study of 1000 male circumcision procedures using the ShangRing device. The primary objective of the study is to enhance understanding of the potential clinical and operational challenges and opportunities that may be associated with widespread use of ShangRing™ device for circumcision in different settings in Mozambique. Specific objectives are: 1) To monitor the proportion of men who choose circumcision through the WHO-prequalified, FDA-approved ShangRing™ device in routine voluntary medical male circumcision (VMMC) service delivery settings where standard surgical methods of circumcisions are available; and 2) To ensure safety during initial implementation of the ShangRing™ device and confirm that adverse event rates are comparable to those found during implementation in other sub-Saharan countries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03761836
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ShangRing
Trials testing the same drug.
- NCT06273696 — Evaluation of the Acceptability and Safety of the ShangRing Device for Male Circumcision in Shinyanga, Tanzania · completed
- NCT03338699 — Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision (EIMC) in Sub-Saharan Africa · NA · completed
Other recruiting trials for Circumcision, Male
Currently open trials in the same condition.
- NCT07052955 — The Effect of Health Riddles on Fear, Anxiety, and Pain in Circumcised Children · NA · recruiting
- NCT06793722 — Technological Devices in Circumcision · NA · recruiting
Other Jhpiego trials
Trials by the same sponsor.
- NCT06258200 — The Role of Gender Transformative Interventions to Strengthen Gender Equity and Improve Immunization Outcomes · NA · active not recruiting
- NCT05774626 — Injectable Contraception Cohort Study in Punjab, Pakistan · completed
- NCT05563974 — Family Led Postnatal Care in Ethiopia · NA · completed
- NCT05565196 — Birth Companion Intervention in Ethiopia, Kenya and Nigeria · NA · completed
- NCT05133661 — SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study) · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03761836 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jhpiego
- Last refreshed: 22 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03761836.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing